Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health
Metabolic Mounjaro · Zepbound

Tirzepatide

Also known as GIP/GLP-1 dual agonist · developed by Eli Lilly

Approved medicine

Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.

Prescription medicine Licensed and available only on prescription in the UK, EU and US. Supply without a prescription is illegal.
Illustration only. Not a photograph of a product, and not an offer of supply — Genexis Health does not sell or supply Tirzepatide.

What it is

A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions that resist degradation and a fatty acid chain for weekly dosing.

How it is thought to work

Dual agonist at GIP and GLP-1 receptors. The contribution of GIP agonism is still debated: it improves insulin sensitivity and may reduce the nausea burden relative to GLP-1 alone, but the mechanism behind the larger weight effect is not settled.

What the studies found

  • Larger weight reduction than GLP-1 alone

    SURMOUNT-1 reported mean weight loss around 21% at 72 weeks at the highest dose. SURMOUNT-5, a head-to-head against semaglutide, found greater reduction with tirzepatide (approximately 20% versus 14%).

  • Strong glycaemic effect

    The SURPASS programme showed HbA1c reductions exceeding comparators including insulin and semaglutide in type 2 diabetes.

  • Obstructive sleep apnoea

    SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, leading to an additional licensed indication.

What the evidence does not show

  • Cardiovascular outcome data is less mature than semaglutide's — SURPASS-CVOT reported non-inferiority to dulaglutide rather than the event reduction SELECT showed.
  • As with semaglutide, weight is regained after discontinuation.
  • The relative contribution of GIP versus GLP-1 agonism remains an open scientific question.

Reported risks and adverse effects

  • Gastrointestinal effects dominate: nausea, diarrhoea, vomiting, constipation, most common during escalation.
  • Same rodent thyroid C-cell finding and the same contraindication as semaglutide.
  • Pancreatitis and gallbladder disease reported.
  • Hypoglycaemia risk rises when combined with insulin or sulfonylureas.

This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.

Regulatory status

Licensed for type 2 diabetes (Mounjaro) and weight management and OSA (Zepbound). Prescription-only in the UK, EU and US.

Where it acts

The sites below are where Tirzepatide is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.

Drag to turn · tap an organ

1234
Stylised illustration. Marker positions are indicative, not anatomically precise.
  1. Dual GIP and GLP-1 receptor agonism reducing energy intake.

    What was measuredSURMOUNT-1 (n≈2,539): mean weight loss ≈20.9% at 72 weeks on the highest dose, the largest reported for an approved drug.

  2. Increases glucose-dependent insulin secretion.

    What was measuredSURPASS programme: HbA1c reductions exceeding semaglutide 1mg in a head-to-head trial in type 2 diabetes.

  3. GIP receptor agonism is proposed to improve insulin sensitivity in adipose tissue.

    What was measuredThe contribution of GIP to the weight effect is debated and not settled. This arm of the mechanism is proposed, not demonstrated.

  4. Reduces obstructive sleep apnoea severity.

    What was measuredSURMOUNT-OSA: clinically meaningful reduction in apnoea-hypopnoea index in adults with obesity and moderate-to-severe OSA.